Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile
New immunotherapy option emerges for low-risk gestational trophoblastic neoplasia
Adding first-line checkpoint inhibition to standard treatment shows promise to improve response in women
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients